Skip to main content
. 2021 Oct 13;6:368. doi: 10.1038/s41392-021-00777-z

Table 1.

Characteristics of participants by COVID-19 severity

No./total No. (%) or median (IQR) Pa
Overall (n = 121) Non-severe (n = 102) Severe (n = 19)
Demographic characteristics
 Age, years 49 (40–57) 48.5 (39–57) 56 (46–59) 0.109
  <30 6 (5) 6 (5.9) 0 (0) 0.588
  >60 14 (11.6) 11 (10.8) 3 (15.8) 0.460
 Female 71 (58.7) 63 (61.8) 8 (42.1) 0.132
 Body mass index 23.9 (22.5–25.6) 23.9 (22.6–25.4) 24.2 (21.9–26) 0.859
 Comorbidity 37 (30.6) 29 (28.4) 8 (42.1) 0.280
  Hypertension 31 (25.6) 26 (25.5) 5 (26.3) 1.00
  Diabetes 8 (6.6) 6 (5.9) 2 (10.5) 0.610
  Autoimmune diseases 2 (1.7) 1 (1) 1 (5.3) 0.290
  Cardiovascular diseases 3 (2.5) 3 (2.9) 0 (0) 1.00
  Cancer 1 (0.8) 1 (1) 0 (0) 1.00
Last follow-up findings
 Symptom onset to last follow-up, days 348 (344–351) 348 (344–351) 347 (339–351) 0.592
 Discharge to last follow-up, days 316 (311–321) 317 (312–323) 312 (300–314) <.001
 Persistent COVID-19-related symptoms 36 (29.8) 21 (20.6) 15 (78.9) <.001
  Respiratory symptoms 22 (18.2) 10 (9.8) 12 (63.2) <.001
  Neurological/mental symptoms 15 (12.4) 9 (8.8) 6 (31.6) 0.014
  Fatigue/weakness 14 (11.6) 7 (6.9) 7 (36.8) 0.001
 Other disease diagnosis after discharge 12 (9.9) 9 (8.8) 3 (15.8) 0.400
 SARS-CoV-2 PCR-positive after discharge 5 (4.1) 5 (4.9) 0 (0) 1.00
 Anti-SARS-CoV-2 IgM positive 2 (1.7) 2 (2) 0 (0) 0.583
  Weakly positive 3 (2.5) 2 (2) 1 (5.3)
  Negative 116 (95.9) 98 (96.1) 18 (94.7)
 Anti-SARS-CoV-2 IgG positive 55 (45.5) 42 (41.2) 13 (68.4) 0.062
  Weakly positive 20 (16.5) 17 (16.7) 3 (15.8)
  Negative 46 (38) 43 (42.2) 3 (15.8)
 Abnormal CT findings at prior follow-ups 21/62 (33.9) 12/48 (25) 9/14 (64.3) 0.010
 Abnormal CT findings at last follow-up 10 (8.3) 0 (0) 10 (52.6) <.001

aP values were calculated by Fisher’s exact test (data with only 1 row) or Chi-square test (multi-row data) for categorical variables, and by Mann–Whitney U test for continuous variables between the two groups